Table 4.
Characteristics of the 10 relapse cases a
| No | Sputum SPCN | Co-morbidity | CXR (cavity) | DOT | Treatment regimen |
|---|---|---|---|---|---|
| 1 | No | Nil | NO | Yes | HER (194 d), Z (8 d) |
| 2 | No | Nil | NO | No | HER (184 d), Z (63 d) |
| 3 | No | Nil | NO | Yes | HER (182 d), Z (77 d) |
| 4 | No | Alcoholism | Yes | Yes | HER (328 d), Z (17 d) |
| 5 | Yes | DM | No | Yes | HER (252 d), Z (84 d) |
| 6# | No | DM | Yes | Yes | HR (539 d), EZ (32 d) |
| 7 | No | DM | Yes | No | HER (310d), Z (30 d) |
| 8 | Yes | Alcoholism | No | Yes | HER (358 d), Z (12 d) |
| 9 | Yes | DM/Alcoholism | Yes | Yes | HER (343 d) |
| 10 | No | Nil | Yes | Yes | HR (231 d), E (21 d), Z (15 d) |
#MDR-TB while relapse; SPCN (smear positive but culture negative); DM, diabetes mellitus; DOT, directly observed therapy; H, Isoniazide; E, Ethambutol; R, Rifampicin; Z, Pyrazinamide.
aPatients who died during the study were excluded.